MCRB Seres Therapeutics Inc.

3.39
+0.05  (+2%)
Previous Close 3.34
Open 3.47
Price To Book -4.99
Market Cap 241,189,635
Shares 71,147,385
Volume 246,265
Short Ratio
Av. Daily Volume 262,204
Stock charts supplied by TradingView

NewsSee all news

  1. Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

     – Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 – – Potential for ECOSPOR III to be a single pivotal study supporting product registration with FDA – – Company assessing the impact

  2. Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET. An audio webcast of the presentation will be

  3. Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration's March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation

    FDA alert is related to unapproved fecal microbiota transplantation (FMT) and does not impact Seres' investigational microbiome therapeutic candidates Seres Therapeutics, Inc. (NASDAQ:MCRB) today provided a statement

  4. Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights

    – Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative colitis in H2 2020 – – Clinical development

  5. Seres Therapeutics to Present at the Cowen 2020 Health Care Conference

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET. A live audio webcast of the presentation will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due mid-2020.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b data due 2H 2020.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2H 2020.
SER-401
Melanoma

Latest News

  1. Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

     – Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 – – Potential for ECOSPOR III to be a single pivotal study supporting product registration with FDA – – Company assessing the impact

  2. Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET. An audio webcast of the presentation will be

  3. Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration's March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation

    FDA alert is related to unapproved fecal microbiota transplantation (FMT) and does not impact Seres' investigational microbiome therapeutic candidates Seres Therapeutics, Inc. (NASDAQ:MCRB) today provided a statement

  4. Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights

    – Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative colitis in H2 2020 – – Clinical development

  5. Seres Therapeutics to Present at the Cowen 2020 Health Care Conference

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET. A live audio webcast of the presentation will

  6. Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 2, 2020 at 8:30 a.m. ET to discuss fourth quarter and full year 2019 results and provide

  7. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  8. Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz, M.D., has decided to step down after serving as Chairman of the Board

  9. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  10. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  11. Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET. A live audio webcast of the presentation

  12. Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update

    – Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate

  13. Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general

  14. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  15. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  16. 4BIO Capital raises $50 million in first close of new advanced therapies fund

    Press Release 4BIO Capital raises $50 million in first close of new advanced therapies fund             4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close 9 September 2019